Integer (NYSE:ITGR) Hits New 12-Month Low – Should You Sell?

Integer Holdings Corporation (NYSE:ITGR)’s share price hit a new 52-week low during trading on Thursday . The company traded as low as $92.00 and last traded at $81.30, with a volume of 33478 shares trading hands. The stock had previously closed at $109.11.

Analyst Ratings Changes

ITGR has been the subject of a number of research analyst reports. Bank of America lowered Integer from a “buy” rating to a “neutral” rating and set a $87.00 target price for the company. in a research report on Friday. Piper Sandler decreased their target price on Integer from $155.00 to $82.00 and set an “overweight” rating for the company in a research report on Friday. Citigroup lowered Integer from a “buy” rating to a “neutral” rating and decreased their target price for the company from $140.00 to $77.00 in a research report on Thursday. Argus lowered Integer from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Wall Street Zen lowered Integer from a “buy” rating to a “hold” rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, Integer presently has an average rating of “Hold” and an average target price of $97.75.

Integer Price Performance

The company has a current ratio of 3.71, a quick ratio of 2.18 and a debt-to-equity ratio of 0.70. The business has a fifty day simple moving average of $103.61 and a 200 day simple moving average of $112.44. The stock has a market capitalization of $2.56 billion, a P/E ratio of 30.52, a price-to-earnings-growth ratio of 0.58 and a beta of 0.97.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, October 23rd. The medical equipment provider reported $1.79 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.11. Integer had a return on equity of 12.84% and a net margin of 4.75%.The firm had revenue of $467.69 million during the quarter, compared to analyst estimates of $466.45 million. During the same period in the previous year, the company posted $1.43 EPS. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. Integer has set its FY 2025 guidance at 6.290-6.430 EPS. On average, analysts expect that Integer Holdings Corporation will post 6.01 earnings per share for the current year.

Hedge Funds Weigh In On Integer

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Tributary Capital Management LLC boosted its stake in shares of Integer by 92.6% in the 3rd quarter. Tributary Capital Management LLC now owns 499,776 shares of the medical equipment provider’s stock worth $51,642,000 after buying an additional 240,226 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Integer by 127.3% in the 3rd quarter. SG Americas Securities LLC now owns 45,951 shares of the medical equipment provider’s stock worth $4,748,000 after buying an additional 25,732 shares during the last quarter. KLP Kapitalforvaltning AS boosted its stake in shares of Integer by 7.1% in the 3rd quarter. KLP Kapitalforvaltning AS now owns 7,500 shares of the medical equipment provider’s stock worth $775,000 after buying an additional 500 shares during the last quarter. Cerity Partners LLC boosted its stake in shares of Integer by 344.2% in the 3rd quarter. Cerity Partners LLC now owns 118,468 shares of the medical equipment provider’s stock worth $12,241,000 after buying an additional 91,797 shares during the last quarter. Finally, North Growth Management Ltd. boosted its stake in shares of Integer by 5.1% in the 3rd quarter. North Growth Management Ltd. now owns 103,000 shares of the medical equipment provider’s stock worth $10,593,000 after buying an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.